UEndocrine Blog

Hello World,

Welcome to the UEndocrine.com blog. This ever-changing space will be the home to news and opinion in the world of endocrinology, specifically the areas of diabetes, lipid and bone disorders and therapeutics. We are actively recruiting leading experts in the field of endocrinology and know that this will become a vibrant space for visitors to learn and comment on the important issues affecting endocrinology. If you would like to become a contributor to this blog or if you would like to learn more about it please contact us here.

Longer term data is now available comparing once weekly exenatide and daily insulin glargine in patients with Type II diabetes. All patients, also on various antihyperglycemics, had HbA1C between 7 and 11% and were treated with either 2 mg of weekly SC exenatide or glargine titrated to a fasting blood glucose 5.5 mmol/L.

Degludec is an ultralong-acting insulin with a half-life is >25 hours, nearly twice that of glargine (Lantus) which according to 2 new non-inferiority studies, could reduce the risk of overnight hypoglycaemia. Two studies, one evaluating 629 patients with type 1 diabetes and another with 744 patients with advanced type 2 diabetes insulin degludec was compared with insulin glargine in basal-bolus insulin regimens. In both studies, patients were treated to target and evaluated for hypoglycaemia.